



2022

Corrigendum to “The impact of the rare disease and Orphan Drug Act in Taiwan” [J Food Drug Anal 29 (2021) 717-725]

Follow this and additional works at: <https://www.jfda-online.com/journal>

 Part of the [Food Science Commons](#), [Medicinal Chemistry and Pharmaceutics Commons](#), [Pharmacology Commons](#), and the [Toxicology Commons](#)



This work is licensed under a [Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License](#).

Recommended Citation

(2022) "Corrigendum to “The impact of the rare disease and Orphan Drug Act in Taiwan” [J Food Drug Anal 29 (2021) 717-725]," *Journal of Food and Drug Analysis*: Vol. 30 : Iss. 2 , Article 11.
Available at: <https://doi.org/10.38212/2224-6614.3407>

This Corrigendum is brought to you for free and open access by Journal of Food and Drug Analysis. It has been accepted for inclusion in Journal of Food and Drug Analysis by an authorized editor of Journal of Food and Drug Analysis.

Corrigendum to “The impact of the rare disease and Orphan Drug Act in Taiwan” [J Food Drug Anal 29 (2021) 717–725]

Ning-Chun Hsiang^a, Weng-Foung Huang^b, Churn-Shiouh Gau^a,
Teng-Wen Tsai^a, Lin-Chau Chang^{a,*}

^a School of Pharmacy, College of Medicine, National Taiwan University, 33 Linsen S. Rd., Zhongzheng Dist., Taipei City, 10050, Taiwan

^b Institute of Health and Welfare Policy, National Yang Ming Chiao Tung University, 155, Sec. 2, Linong Street, Beitou Dist., Taipei City, 11221, Taiwan

The capitalization in the title is not appropriate. Since “The Rare Disease and Orphan Drug Act” is the name of the Act, we would like the title of our manuscript to be capitalized as follows: “The impact of The Rare Disease and Orphan Drug Act in Taiwan”. This change would also influence the style of title in the section “Recommended Citation”. Similarly, the capitalization issue also prevails in the reference list stated as follows: Reference 4: The title of the journal article should be “The Orphan Drug Act revisited”; Reference 7: The reference should start with “The Rare Disease and Orphan Drug Act (Taiwan) announced in 2000, last amended in 2015 [Internet].” Reference 20: The reference should start with “Annual reports for

drugs to which The Rare Disease and Orphan Drug Act is applicable [Internet].” Reference 23: The reference should start with “Items to which The Rare Disease and Orphan Drug Act is applicable, special drugs, and relevant regulations for rare diseases [Internet].” Reference 37: The reference should start with “Regulations for National Health Insurance Pharmaceutical Benefits and Reimbursement Scheme announced in 1999, last amended in 2020 (Chinese) [Internet].” Besides, for the Reference 11, there is an additional punctuation within the name of the Act. For Reference 11, the reference should start with “National Health Insurance Act (Taiwan) announced in 1994, last amended in 2020 [Internet].”

DOI of original article: <https://doi.org/10.38212/2224-6614.3407>.

Available online 15 June 2022

* Corresponding author at: School of Pharmacy, College of Medicine, National Taiwan University, 33 Linsen S. Rd., Zhongzheng Dist., Taipei City, 10050, Taiwan. Fax: +886 2 33919098.
E-mail address: linchauchang@ntu.edu.tw (L-C. Chang).

<https://doi.org/10.38212/2224-6614.3407>

2224-6614/© 2022 Taiwan Food and Drug Administration. This is an open access article under the CC-BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).